-
Mashup Score: 1Qian Qin: Tian Zhang with kidney trial updates at Alliance for Clinical Trials in Oncology Fall 24 meeting - OncoDaily - 6 day(s) ago
Qian Qin: Tian Zhang with kidney trial updates at Alliance for Clinical Trials in Oncology Fall 24 meeting / Alliance for Clinical Trials in Oncology, cancer,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Defining Disease Burden and Cure - 2 month(s) ago
Share your voice and help improve care for all kidney cancer patients!
Source: www.surveymonkey.comCategories: General Medicine News, Hem/OncsTweet-
Calling all patients w #kidneycancer and their amazing caregivers! Take this survey from @kcCURE & help us understand perceptions of disease burden and — dare we say! — what cure means to you. https://t.co/oOON5VC0IW @LauraEsfeller @kaydaustin @RCCadvocate https://t.co/FkG8lhMTRn
-
-
Mashup Score: 44Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | NEJM - 2 month(s) ago
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet-
@tompowles1 presents #NIAGARA trial - first in #bladdercancer to show IO benefit for neoadjuvant durvalumab-chemo -- improved event free survival and overall survival. Concurrent @NEJM publication today! https://t.co/PmvdyWD5Oc @myESMO @OncoAlert #ESMO24 #ESMOAmbassadors https://t.co/AYxMFiuzy5
-
-
Mashup Score: 44Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | NEJM - 2 month(s) ago
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet-
@tompowles1 presents #NIAGARA trial - first in #bladdercancer to show IO benefit for neoadjuvant durvalumab-chemo -- improved event free survival and overall survival. Concurrent @NEJM publication today! https://t.co/PmvdyWD5Oc @myESMO @OncoAlert #ESMO24 #ESMOAmbassadors https://t.co/AYxMFiuzy5
-
-
Mashup Score: 33
These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.
Source: www.thelancet.comCategories: General Medicine News, UrologyTweet-
@DrChoueiri presents #TiNivo2 showing no benefit of combination in IO-refractory #kidneycancer — supports tivozanib 1.34mg monotherapy. Results published in @TheLancet today https://t.co/DPQ3LvY1zP #ESMO24 @myESMO #ESMOAmbassadors https://t.co/MJVAArbP5b
-
-
Mashup Score: 33
These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.
Source: www.thelancet.comCategories: General Medicine News, UrologyTweet-
@DrChoueiri presents #TiNivo2 showing no benefit of combination in IO-refractory #kidneycancer — supports tivozanib 1.34mg monotherapy. Results published in @TheLancet today https://t.co/DPQ3LvY1zP #ESMO24 @myESMO #ESMOAmbassadors https://t.co/MJVAArbP5b
-
-
Mashup Score: 4
A discussion targeted towards successes and challenges in your career. Agenda (ET) 7:00pm-7:05pm: Welcome, Ulka Vaishampayan & Tian Zhang 7:05pm-7:40pm: Successes & Challenges: My Path to Leadership with discussion, Lynn Schuchter, MD, FASCO 7:40pm-8:10pm: Rising Women in RCC mini presentations 8:10pm-8:25pm: Testimonials from group coaching participants 8:25pm-8:30pm: Closing Remarks
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
Register here & save the date! 7/17! https://t.co/PjEMKb7kqw
-
-
Mashup Score: 15ClinicalTrials.gov - 5 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
Importantly we have opened a multicenter IST led by @Dr_Aggen @DrRosenbergMSK for these patients w LN met bladder cancer — ECLIPSE-EV will teach us much about these patients! Open and accruing @utswcancer @MSKCancerCenter & other centers! https://t.co/aTQChUmNCJ
-
-
Mashup Score: 27
A discussion targeted towards successes and challenges in your career. Agenda (ET) 7:00pm-7:05pm: Welcome, Ulka Vaishampayan & Tian Zhang 7:05pm-7:40pm: Successes & Challenges: My Path to Leadership with discussion, Lynn Schuchter, MD, FASCO 7:40pm-8:10pm: Rising Women in RCC mini presentations 8:10pm-8:25pm: Testimonials from group coaching participants 8:25pm-8:30pm: Closing Remarks
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
Join our #WomeninRCC webinar on July 17! Grateful to @lynn_schuchter for her time & wisdom. Will also have 3 early career women recap their #ASCO24 presentations. Thanks @KidneyCancer for organizing! Register here: https://t.co/SGxaIDbwS5 https://t.co/pubPKnZmEP
-
-
Mashup Score: 2Metastatic Urothelial Carcinoma mUC — Current Activities - 5 month(s) ago
This CME-certified activity will focus on best practices in the care of patients with mUC.
Source: www.bonumce.comCategories: General Medicine News, Hem/OncsTweet-
@BonumCe 4/ #MedTwitter #OncTwitter #gucsm #MetastaticUrothelialCarcinoma #CME➡️https://t.co/yieUjIHRxv 🟢Pre-poll question3️⃣ 📊75yo woman w/ newly diagnosed PD-L1+ #mUC GFR of 25mL/min. According to the #EAU guidelines, which would be an appropriate 1L treatment option for her?
-
RT @oncodaily: Dr. @TiansterZhang with kidney trial updates at @ALLIANCE_org Fall 24 meeting - @QianJanieQin https://t.co/uBUYpM3fwS #Ca…